American Public Health Champion Receives 2010 Stockholm Water Prize

STOCKHOLM, Sweden, March 22, 2010 – Dr. Rita Colwell, distinguished Professor from the University of Maryland
and John Hopkins University's Bloomberg School of Public Health in the United
States, has been named the 2010 Stockholm Water Prize Laureate. Dr. Colwell's
pioneering research on the prevention of waterborne infectious diseases has
helped protect the health and lives of millions.

[...]

First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity

Spasticity Affects a Significant Number of Post-Stroke Patients, [1],[2],[3] and Many are not Adequately Treated by Standard Therapy [4]

TOLOCHENAZ, Switzerland, March 23, 2010 – Medtronic, Inc. (NYSE: MDT) today announced the enrollment of
the first European patients in the largest randomized controlled trial to
date to investigate the benefits of ITB Therapy(R) (Intrathecal Baclofen) in
post-stroke patients [...]

US District Court Returns Binding Verdict of Invalidity of Two Claims of Covidien Patent Covering Trocar Seal Technology

Applied Medical to Pursue Post-Trial Motions to Overturn Covidien Infringement Verdict

ORANGE COUNTY, California, March 23, 2010 – Applied Medical announced today that a United States District Court jury
for the Eastern District of Texas returned a binding verdict of invalidity of
two claims of a Covidien patent covering trocar seal technology.
Applied Medical [...]

Frost & Sullivan: Visual Collaboration in the Future of Healthcare

Frost & Sullivan to Host Analyst Briefing on Visual Collaboration in Healthcare Industry on Thursday, 1 April 2010 at 14.00 BST

LONDON, March 23, 2010 – Evolving patients' needs, limited number of medical specialists in remote
areas, and technological advances are some of the most important factors
driving interest in visual collaboration in healthcare. Patients become
keener to [...]

New Report: BSR’s HERproject Empowers Women and Improves Business in Six Countries

SAN FRANCISCO, March 23, 2010 – BSR's (www.bsr.org) HERproject (www.herproject.org) — a
factory-based women's health initiative — has significantly improved women's
health awareness, leadership skills, and relationships with their employers,
according to a new BSR report
(www.bsr.org/reports/BSR_HERproject_Investing_In_Women.pdf) revealing
results of research conducted after the first year of HERproject programs in
China, Egypt, India, Mexico, Pakistan, and Vietnam.

[...]

Boston Scientific Announces Availability of New Connector System Designed to Simplify the Implant Procedure for Cardiac Devices

PARIS, March 24, 2010 – Boston Scientific Corporation (NYSE: BSX) today announced
European commercial availability of the Company's new cardiac rhythm
management connector system, which consists of the ENDOTAK RELIANCE(R) 4-SITE
defibrillation lead and compatible COGNIS(R) cardiac resynchronization
therapy defibrillators (CRT-Ds) and TELIGEN(R) implantable cardioverter
defibrillators (ICDs). The system is designed to simplify the implant
procedure by combining three terminals [...]

Property Industry has Critical Role in Improving Well-being in Britain

LONDON, March 24, 2010 – A new report launched today, Building Quality of Life,
commissioned by Development Securities PLC, one of the UK's leading property
companies, reveals the huge pressures on our general happiness and well-being
and the key contribution that the property industry can make to improving
quality of life in Britain.

The research, [...]

ViroPharma Announces Acceptance of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Marketing Authorization Application (MAA) by European Medicines Agency (EMA)

EXTON, Pennsylvania, March 24, 2010 – ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European
Medicines Agency (EMA) has accepted the filing of its Marketing Authorization
Application (MAA) for Cinryze for acute treatment and prophylaxis against
hereditary angioedema (HAE), which was submitted through the centralized
procedure in March 2010. ViroPharma is seeking European approval for both
prevention and treatment [...]

The CPM Resource Center Healthcare Consortium Earns Prestigious Award From The National Academies of Practice Interdisciplinary Group Recognition Award Lauds CPM Resource Center’s Healthcare Consortium

GRAND RAPIDS, Michigan, March 24, 2010 – The Healthcare Consortium of the Clinical Practice Model
Resource Center (CPMRC, www.cpmrc.com/), an Elsevier company, is the
2010 recipient of the National Academies Practice (NAP) Interdisciplinary
Group Recognition Award. Bestowed annually on groups that make "enduring
contributions to interdisciplinary education and practice," the NAP
(www.napractice.org/ ) award recognizes CPMRC's 25-year-old Healthcare
Consortium of [...]

Agendia Launches BluePrint(TM) Expanding Breast Cancer Product Offering

New Service to Provide Breast Cancer Molecular Subtyping
HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010 – Agendia, a world leader in molecular cancer diagnostics, today announced
that its breast cancer product offering, consisting of breast cancer
recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with
BluePrint (TM) to report important additional information on tumor subtypes.
This new service [...]

Shire Presents Positive Data for Patients With Type 1 Gaucher Disease Who Switched to VPRIV(TM)

Also Reported are Results of Retrospective Analysis of Phase I/II Study, Showing Success in Reaching Therapeutic Goals within 4 Years of Initiation of Treatment

CAMBRIDGE, Massachusetts, March 25, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today presented positive data from a Phase III
clinical trial (TKT-034) designed to evaluate the safety [...]

Boston Scientific Announces Availability of New Connector System Designed to Simplify the Implant Procedure for Cardiac Devices

PARIS, March 24, 2010 – Boston Scientific Corporation (NYSE: BSX) today announced
European commercial availability of the Company's new cardiac rhythm
management connector system, which consists of the ENDOTAK RELIANCE(R) 4-SITE
defibrillation lead and compatible COGNIS(R) cardiac resynchronization
therapy defibrillators (CRT-Ds) and TELIGEN(R) implantable cardioverter
defibrillators (ICDs). The system is designed to simplify the implant
procedure by combining three terminals [...]

Property Industry has Critical Role in Improving Well-being in Britain

LONDON, March 24, 2010 – A new report launched today, Building Quality of Life,
commissioned by Development Securities PLC, one of the UK's leading property
companies, reveals the huge pressures on our general happiness and well-being
and the key contribution that the property industry can make to improving
quality of life in Britain.

The research, [...]

ViroPharma Announces Acceptance of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Marketing Authorization Application (MAA) by European Medicines Agency (EMA)

EXTON, Pennsylvania, March 24, 2010 – ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European
Medicines Agency (EMA) has accepted the filing of its Marketing Authorization
Application (MAA) for Cinryze for acute treatment and prophylaxis against
hereditary angioedema (HAE), which was submitted through the centralized
procedure in March 2010. ViroPharma is seeking European approval for both
prevention and treatment [...]

The CPM Resource Center Healthcare Consortium Earns Prestigious Award From The National Academies of Practice Interdisciplinary Group Recognition Award Lauds CPM Resource Center’s Healthcare Consortium

GRAND RAPIDS, Michigan, March 24, 2010 – The Healthcare Consortium of the Clinical Practice Model
Resource Center (CPMRC, www.cpmrc.com/), an Elsevier company, is the
2010 recipient of the National Academies Practice (NAP) Interdisciplinary
Group Recognition Award. Bestowed annually on groups that make "enduring
contributions to interdisciplinary education and practice," the NAP
(www.napractice.org/ ) award recognizes CPMRC's 25-year-old Healthcare
Consortium of [...]

Agendia Launches BluePrint(TM) Expanding Breast Cancer Product Offering

New Service to Provide Breast Cancer Molecular Subtyping
HUNTINGTON BEACH, California and AMSTERDAM, March 24, 2010 – Agendia, a world leader in molecular cancer diagnostics, today announced
that its breast cancer product offering, consisting of breast cancer
recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with
BluePrint (TM) to report important additional information on tumor subtypes.
This new service [...]

FDA Advisory Panel Unanimously Recommends Expanded Indication for Boston Scientific’s Heart Failure Devices Based on Landmark MADIT-CRT Trial

Company's CRT-Ds Recommended for Asymptomatic and Mild Heart Failure Patients

NATICK, Massachusetts, March 23, 2010 – Boston Scientific Corporation (NYSE: BSX) today announced that the
Circulatory System Devices Panel of the U.S. Food and Drug Administration
(FDA) has unanimously recommended approval of an expanded indication for its
cardiac resynchronization therapy defibrillators (CRT-Ds), including the
COGNIS(R) CRT-D. The panel recommended [...]

First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity

Spasticity Affects a Significant Number of Post-Stroke Patients, [1],[2],[3] and Many are not Adequately Treated by Standard Therapy [4]

TOLOCHENAZ, Switzerland, March 23, 2010 – Medtronic, Inc. (NYSE: MDT) today announced the enrollment of
the first European patients in the largest randomized controlled trial to
date to investigate the benefits of ITB Therapy(R) (Intrathecal Baclofen) in
post-stroke patients [...]

US District Court Returns Binding Verdict of Invalidity of Two Claims of Covidien Patent Covering Trocar Seal Technology

Applied Medical to Pursue Post-Trial Motions to Overturn Covidien Infringement Verdict

ORANGE COUNTY, California, March 23, 2010 – Applied Medical announced today that a United States District Court jury
for the Eastern District of Texas returned a binding verdict of invalidity of
two claims of a Covidien patent covering trocar seal technology.
Applied Medical [...]

Frost & Sullivan: Visual Collaboration in the Future of Healthcare

Frost & Sullivan to Host Analyst Briefing on Visual Collaboration in Healthcare Industry on Thursday, 1 April 2010 at 14.00 BST

LONDON, March 23, 2010 – Evolving patients' needs, limited number of medical specialists in remote
areas, and technological advances are some of the most important factors
driving interest in visual collaboration in healthcare. Patients become
keener to [...]

New Report: BSR’s HERproject Empowers Women and Improves Business in Six Countries

SAN FRANCISCO, March 23, 2010 – BSR's (www.bsr.org) HERproject (www.herproject.org) — a
factory-based women's health initiative — has significantly improved women's
health awareness, leadership skills, and relationships with their employers,
according to a new BSR report
(www.bsr.org/reports/BSR_HERproject_Investing_In_Women.pdf) revealing
results of research conducted after the first year of HERproject programs in
China, Egypt, India, Mexico, Pakistan, and Vietnam.

[...]

First Personal Injury on Asbestos in Schools

MANCHESTER, England, March 22, 2010 – Accident claims (www.firstpersonalinjury.co.uk/) solicitors, First
Personal Injury, want to see more advice made readily available to parents
and pupils about asbestos exposure in schools. The call comes less than a
month after a report by the Asbestos Training and Consultancy Association
(ATAC) made news for all the wrong reasons.

[...]

American Public Health Champion Receives 2010 Stockholm Water Prize

STOCKHOLM, Sweden, March 22, 2010 – Dr. Rita Colwell, distinguished Professor from the University of Maryland
and John Hopkins University's Bloomberg School of Public Health in the United
States, has been named the 2010 Stockholm Water Prize Laureate. Dr. Colwell's
pioneering research on the prevention of waterborne infectious diseases has
helped protect the health and lives of millions.

[...]

Theranostics Paves the Way for Personalised Medicine in Europe, Says Frost & Sullivan

LONDON, March 22, 2010 – Theranostics is an emerging field in clinical diagnostics, focussing on
developing specific analysis to predict the most suitable drug for a patient
along with assessing the efficacy of the drug. It uses molecular assays to
determine the optimum dose of drugs for a patient, paving the way for
personalised medicine. Although significant awareness [...]

PRISYM ID’s Medica Greatly Simplifies FDA and MHRA Compliance

Web-Based Solution Allows Faster Rollout, Greater Collaboration and Increased Accuracy When Labelling Pharmaceuticals and Medical Devices

DUBLIN, March 23, 2010 – PRISYM ID Limited today announced the launch of a new product
that allows life science companies to review, validate and record their
product labels quickly and efficiently while allowing greater collaboration
across the process. PRISYM Medica is [...]

Menicon Co. Acquires Tomey Co. to Improve Competitiveness

Menicon takes another step to global expansion by vertical integration -
NAGOYA, Japan, March 19, 2010 – Menicon Co., Ltd. announced on March 17 that it had acquired all shares
of Tomey Co., Ltd. from Tomey Shoji Inc. The deal was completed on February
1, 2010.

Tomey Co. is a major Japan-based manufacturer of [...]

Evidence Suggests That Sleep is a Common Problem for People With a Wide Range of Neurological Conditions

UCB Supports World Sleep Day (19th March 2010)
BRUSSELS, Belgium, March 19, 2010 – Patients with neurological diseases need more help with their associated
sleep-wake disturbances that can often make their underlying illness worse,
say leading sleep specialists attending a sleep meeting hosted by
biopharmaceutical company, UCB, to mark World Sleep Day.

A growing body [...]

Activeion Announces Opening of European Office

Activeion (Europe) GmbH commences operations as the wholly owned subsidiary of Activeion Cleaning Solutions, Rogers, Minnesota, USA

BADEN, Switzerland, March 19, 2010 – Activeion Cleaning Solutions LLC, Rogers, MN USA is proud to announce its
new European subsidiary, Activeion (Europe) GmbH. Activeion (Europe) GmbH
will distribute and market the ionator EXP(TM) throughout Europe, the Middle
East and Africa. [...]

Nobel Prize Winner Dr. Eric Kandel Joins NeuroFocus Advisory Board

Columbia University Professor and Noble Laureate for His Contributions to Neuroscience Brings Expertise in Memory Research to World's Leading Neuromarketing Company

BERKELEY, California, March 19, 2010 – NeuroFocus, the world's leading neuromarketing company, announced today
that Nobel Prize laureate Eric R. Kandel, M.D., has joined its Advisory
Board. Dr. Kandel is a winner of the Nobel Prize [...]

Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers

CAMBRIDGE, England, March 19, 2010 – Mundipharma announced today that the Committee for Medicinal
Products for Human Use (CHMP) of the European Medicines Agency (EMA) has
issued a positive opinion recommending that marketing authorisations can be
granted in Germany and the following Member States of the EU: Austria,
Belgium, Denmark, Finland, France, Ireland, Italy, Luxembourg, Norway,
Poland, Spain and [...]

Eisai Plans to Continue Eritoran (E5564) Phase III Severe Sepsis Trial, Based on Interim Analysis That Evaluated Efficacy and Safety Data

LONDON, March 26, 2010 – Eisai Europe Ltd. announced today that the Phase III ACCESS (A Controlled
Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of
the investigational compound eritoran (E5564) will continue enrolling to the
planned 2,000 patients. As part of a planned interim analysis, an independent
Data Monitoring Committee (DMC) has evaluated efficacy [...]

Shire Presents Positive Data for Patients With Type 1 Gaucher Disease Who Switched to VPRIV(TM)

Also Reported are Results of Retrospective Analysis of Phase I/II Study, Showing Success in Reaching Therapeutic Goals within 4 Years of Initiation of Treatment

CAMBRIDGE, Massachusetts, March 25, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, today presented positive data from a Phase III
clinical trial (TKT-034) designed to evaluate the safety [...]